Kandhavelu, J. Et Al. 2024. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer. BRITISH JOURNAL OF PHARMACOLOGY , vol.181, no.1 , 107-124.

Kandhavelu, J., Subramanian, K., Naidoo, V., Sebastianelli, G., Doan, P., Mani, S. K., ... YAPIŞLAR, H.(2024). A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer. BRITISH JOURNAL OF PHARMACOLOGY , vol.181, no.1, 107-124.

Kandhavelu, Jeyalakshmi Et Al. "A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer," BRITISH JOURNAL OF PHARMACOLOGY , vol.181, no.1, 107-124, 2024

Kandhavelu, Jeyalakshmi Et Al. "A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer." BRITISH JOURNAL OF PHARMACOLOGY , vol.181, no.1, pp.107-124, 2024

Kandhavelu, J. Et Al. (2024) . "A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer." BRITISH JOURNAL OF PHARMACOLOGY , vol.181, no.1, pp.107-124.

@article{article, author={Jeyalakshmi Kandhavelu Et Al. }, title={A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer}, journal={BRITISH JOURNAL OF PHARMACOLOGY}, year=2024, pages={107-124} }